Consolidation With Second High Dose Therapy and Autologous Stem Cell Transplantation Is Associated With Improved Overall Survival in Patients With Multiple Myeloma in First Relapse
This study highlights the viability of second HDT/ASCT as treatment option for relapsed MM, particularly for patients with good responses to first-line HDT/ASCT. In the era of novel agents, second HDT/ASCT should be considered a feasible and effective consolidative strategy.
Authors
- Wilfried W. H. Roeloffzen (ORCID: https://orcid.org/0000-0003-3976-8001)
- Marcel Nijland (ORCID: https://orcid.org/0000-0002-2740-2873)
- Wouter J. Plattel (ORCID: https://orcid.org/0000-0001-9828-9460)
- Gerwin A. Huls (ORCID: https://orcid.org/0000-0002-7120-898X)
- Hilde Kooistra (ORCID: https://orcid.org/0009-0006-3254-8064)
- Koen M Klomberg (ORCID: https://orcid.org/0009-0007-8902-4162)
- Miriam Gelderloos
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
Publication Details
- Journal
- Clinical Lymphoma Myeloma & Leukemia
- Published
- 2024-12-24
- DOI
- https://doi.org/10.1016/j.clml.2024.12.010
- Citations
- 1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.45
Funders
- Pfizer
- Celgene
- Cilag